Cytokine-mediated obesity stimulates intestinal cancer

A new study describes themechanistic relationship between thecytokine interleukin-1β(IL-1β) and obesity. WhenIL-1βlevels increase in obesity, theactivation ofIL-1receptor signaling leads to a large number of colon cancers. Kinds of ways. This study shows that obesity is related tothe systemic increase ofIL-1β,the  activation ofWntand the proliferation of mouse colon cells.

Joel Mason of Tufts University in Massachusetts and Tufts University School of Medicine and colleagues at Tufts University co-authored the article ” Interleukin- 1 Signaling Mediates Obesity-Promoted Increased Inflammatory Cytokines, Wnt Activation, and Small ” Proliferation of rat colonic epithelial cells ” article. “

The researchers set out to determine the role of IL-1β in regulating events leading to obesity-promoting colorectal cancer. They compared the role of IL-1β in mice fed a high-fat (obese) or low-fat (lean) diet. One of the changes they are found in obese mice having colon mucosa 30-80 % higher concentration of IL-l [beta] , the Wnt cascade significantly increased signal amplification and significantly proliferating crypts in the colon region.

“This study reveals the close link between obesity and inflammatory response, and reflects the extensive role of IL-1β , defining obesity as one of many inflammatory diseases, ” Department of Immunology , Washington University, Center for Innate Immunity and Immune Diseases. Michael Gale Jr. , editor-in-chief of Journal of Interferon & Cytokine Research, said.

Susan Hau

Website |  + postsBio ⮌

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

• Susan Hau

  https://cancerfax.com/author/susan/

  Datopotamab deruxtecan-dlnk is approved by the USFDA for EGFR-mutated non-small cell lung cancer
• Susan Hau

  https://cancerfax.com/author/susan/

  PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy
• Susan Hau

  https://cancerfax.com/author/susan/

  Neoadjuvant and adjuvant pembrolizumab is approved by the USFDA for resectable locally advanced head and neck squamous cell carcinoma
• Susan Hau

  https://cancerfax.com/author/susan/

  Taletrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer

• Comments Closed
• May 13th, 2020